There’s a new player in the liquid biopsy field. Thrive Earlier Detection Corp., announced late last month that it has launched and has raised $110 million in its Series A round.

Inivata has developed the InVision platform based on research from the Cancer Research UK Cambridge Institute at the University of Cambridge. Its lead product, InVisionFirst-Lung, is commercially available and was develo..

?The latest bit of activity comes from Saga Diagnostics, a Lund, Sweden based company that has raised $4.1 million in a financing round.

Liquid biopsy has attracted a surge of companies that are trying to change the way cancer is detected and monitored.

Upon closing of the transaction, Burlington, the MA-based company will be a subsidiary of Bracco Imaging, led by its current leadership team.

The San Francisco-based company said it signed a definitive agreement to acquire Singular Bio for $55 million.

Genomic Health said recently that the German Federal Joint Committee (G-BA) has issued a positive reimbursement decision for its Oncotype DX Breast Recurrence Score test following...

Recently, BD (Becton, Dickinson and Company) announced the appointment of Puneet Sarin as the global president of BD Bioscience, which took effect on the same day.

Recently, the 2019 Siemens Pharmaceutical Industry Summit was successfully held in Chengdu. During the conference, the world's leading biopharmaceutical industry supplier Sartorius Stedim Biotech and Siemens announced ...

Personalis announced recently that it has priced its initial public offering of around 7.9 million shares of common stock at $17 per share.

Amoy Diagnostics, Premia Holdings, and Loxo Oncology recently announced a partnership aimed at genetic screening of patients for a targeted cancer therapy.

Almac Diagnostic Services recently announced that it has received CE marking for a next-generation sequencing-based diagnostic assay that will be used to ...

Thermo Fisher Scientific recently announced a number of new partnerships in conjunction with the annual American Society for Mass Spectrometry Conference in Atlanta.

Horizon Therapeutics has partnered with Invitae for its urea cycle disorder genetic (UCD) testing program, through which individuals who may have the rare genetic condition and their family members will receive testing at no charge.

Becton Dickinson reported today that its fiscal second quarter revenues decreased approximately 1 percent year over year.